Nexalin Technology

Nexalin Technology FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Nexalin Technology (NXL) as of Nov 11, 2026 is 61.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 54.09 % — a change of 13.65% (higher).

FCF Conversion

61.47 %

YoY

13.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Nexalin Technology is 2025 61.47 % . FCF Conversion Rate (FCF/EBITDA) of Nexalin Technology was 2024 54.09 % . It decreases by 13.65% higher compared to the previous year.

The Nexalin Technology FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
13.51 USD
Jan 1, 2020
25.39 USD
Jan 1, 2021
17.72 USD
Jan 1, 2022
130.50 USD
Jan 1, 2023
84.86 USD
Jan 1, 2024
54.09 USD
Jan 1, 2025
61.47 USD
The Nexalin Technology FCF Conversion history
YEARFCF ConversionYoY
61.47 %+13.65%
54.09 %-36.26%
84.86 %-34.98%
130.50 %+636.63%
17.72 %-30.22%
25.39 %+87.94%
13.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

FCF Conversion Rate (FCF/EBITDA) of Nexalin Technology is 61.47 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Nexalin Technology changed from 54.09 % to 61.47 %, representing a 13.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Nexalin Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nexalin Technology

All Key Metrics — Nexalin Technology